This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bergmann, U. Articles by Korc, M. Search for Related Content PubMed PubMed Citation Articles by Bergmann, U. Articles by Korc, M.

Insulin-like Growth Factor I Overexpression in Human Pancreatic Cancer: Evidence for Autocrine and Paracrine Roles¹

Departments of Medicine and Biological Chemistry, University of California, Irvine, California 92717 [U. B., H. F., M. Y., M. K.], and Department of General Surgery, University of Ulm, D-89075 Ulm, Germany [H. G. B.]

We assessed the potential roles of insulin-like growth factor-I (IGF-I) and the IGF-I receptor (IGF-IR) in human pancreatic cancer. IGF-I enhanced the growth of ASPC-1 and COLO-357 human pancreatic cancer cells, and this effect was significantly inhibited by a highly specific monoclonal anti-IGF-IR antibody (IR3). Both cell lines expressed mRNA transcripts for IGF-IR, and basal cell growth was significantly reduced by an IGF-IR antisense oligodeoxynucleotide. IGF-I mRNA transcripts were not detected in either cell line or in two additional pancreatic cancer cell lines. In contrast, analysis of 12 pancreatic cancers revealed a 32-fold increase (P < 0.01) in IGF-I mRNA levels by comparison with the low levels observed in the normal pancreas. By in situ hybridization, IGF-I mRNA grains were present in both the cancer cells and in the surrounding connective tissue. Six of the cancers exhibited a 4.4-fold increase in IGF-IR mRNA levels. These findings suggest that IGF-I may participate in aberrant autocrine and paracrine activation of IGF-IR in pancreatic cancer in vivo.

¹ This study was supported by USPHS Grants CA-40162 and DK-44948 awarded by the NIH (to M. K.). U. B. was supported by Deutsche Forschungsgemeinschaft, Grant Be 1762/1-1.

² To whom requests for reprints should be addressed, at Division of Endocrinology, Diabetes and Metabolism, Medical Sciences I, C240, University of California, Irvine, CA 92717.

Received 3/ 7/95. Accepted 4/ 5/95.

This article has been cited by other articles:

				A. Vonlaufen, P. A. Phillips, Z. Xu, D. Goldstein, R. C. Pirola, J. S. Wilson, and M. V. Apte Pancreatic Stellate Cells and Pancreatic Cancer Cells: An Unholy Alliance Cancer Res., October 1, 2008; 68(19): 7707 - 7710. [Abstract] [Full Text] [PDF]

				W. Piao, Y. Wang, Y. Adachi, H. Yamamoto, R. Li, A. Imsumran, H. Li, T. Maehata, M. Ii, Y. Arimura, et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas Mol. Cancer Ther., June 1, 2008; 7(6): 1483 - 1493. [Abstract] [Full Text] [PDF]

				W. Liu, D. A. Bloom, W. G. Cance, E. V. Kurenova, V. M. Golubovskaya, and S. N. Hochwald FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells Carcinogenesis, June 1, 2008; 29(6): 1096 - 1107. [Abstract] [Full Text] [PDF]

				K. Takagi, T. S. Dexheimer, C. Redon, O. Sordet, K. Agama, G. Lavielle, A. Pierre, S. E. Bates, and Y. Pommier Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters Mol. Cancer Ther., December 1, 2007; 6(12): 3229 - 3238. [Abstract] [Full Text] [PDF]

				S. A. Lang, C. Moser, A. Gaumann, D. Klein, G. Glockzin, F. C. Popp, M. H. Dahlke, P. Piso, H. J. Schlitt, E. K. Geissler, et al. Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1{alpha} Autocrine Loop, and Reduces Orthotopic Tumor Growth Clin. Cancer Res., November 1, 2007; 13(21): 6459 - 6468. [Abstract] [Full Text] [PDF]

				M. Edderkaoui, P. Hong, J. K. Lee, S. J. Pandol, and A. S. Gukovskaya Insulin-like Growth Factor-I Receptor Mediates the Prosurvival Effect of Fibronectin J. Biol. Chem., September 14, 2007; 282(37): 26646 - 26655. [Abstract] [Full Text] [PDF]

				B. M. Wolpin, D. S. Michaud, E. L. Giovannucci, E. S. Schernhammer, M. J. Stampfer, J. E. Manson, B. B. Cochrane, T. E. Rohan, J. Ma, M. N. Pollak, et al. Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer Cancer Res., August 15, 2007; 67(16): 7923 - 7928. [Abstract] [Full Text] [PDF]

				A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF]

				S. C Larsson, L. Bergkvist, and A. Wolk Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1171 - 1176. [Abstract] [Full Text] [PDF]

				A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]

				T. Asano, Y. Yao, S. Shin, J. McCubrey, J. L. Abbruzzese, and S. A.G. Reddy Insulin Receptor Substrate Is a Mediator of Phosphoinositide 3-Kinase Activation in Quiescent Pancreatic Cancer Cells Cancer Res., October 15, 2005; 65(20): 9164 - 9168. [Abstract] [Full Text] [PDF]

				M. Furukawa, M. Raffeld, C. Mateo, A. Sakamoto, T. W. Moody, T. Ito, D. J. Venzon, J. Serrano, and R. T. Jensen Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases Clin. Cancer Res., May 1, 2005; 11(9): 3233 - 3242. [Abstract] [Full Text] [PDF]

				R. Z. Stolzenberg-Solomon, P. Limburg, M. Pollak, P. R. Taylor, J. Virtamo, and D. Albanes Insulin-Like Growth Factor (IGF)-1, IGF-Binding Protein-3, and Pancreatic Cancer in Male Smokers Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 438 - 444. [Abstract] [Full Text]

				M. Neid, K. Datta, S. Stephan, I. Khanna, S. Pal, L. Shaw, M. White, and D. Mukhopadhyay Role of Insulin Receptor Substrates and Protein Kinase C-{zeta} in Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Pancreatic Cancer Cells J. Biol. Chem., February 6, 2004; 279(6): 3941 - 3948. [Abstract] [Full Text] [PDF]

				Y. Min, Y. Adachi, H. Yamamoto, H. Ito, F. Itoh, C.-T. Lee, S. Nadaf, D. P. Carbone, and K. Imai Genetic Blockade of the Insulin-like Growth Factor-I Receptor: A Promising Strategy for Human Pancreatic Cancer Cancer Res., October 1, 2003; 63(19): 6432 - 6441. [Abstract] [Full Text] [PDF]

				O. Stoeltzing, W. Liu, N. Reinmuth, F. Fan, A. A. Parikh, C. D. Bucana, D. B. Evans, G. L. Semenza, and L. M. Ellis Regulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer Am. J. Pathol., September 1, 2003; 163(3): 1001 - 1011. [Abstract] [Full Text] [PDF]

				E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X.-M. Zhou, W. A. Blattler, T. Chittenden, and R. Singh An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation Cancer Res., August 15, 2003; 63(16): 5073 - 5083. [Abstract] [Full Text] [PDF]

				V. M. Bondar, B. Sweeney-Gotsch, M. Andreeff, G. B. Mills, and D. J. McConkey Inhibition of the Phosphatidylinositol 3'-Kinase-AKT Pathway Induces Apoptosis in Pancreatic Carcinoma Cells in Vitro and in Vivo Mol. Cancer Ther., October 1, 2002; 1(12): 989 - 997. [Abstract] [Full Text] [PDF]

				W Zumkeller IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? Mol. Pathol., October 1, 2001; 54(5): 285 - 288. [Abstract] [Full Text] [PDF]

				D. S. Michaud, E. Giovannucci, W. C. Willett, G. A. Colditz, M. J. Stampfer, and C. S. Fuchs Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer JAMA, August 22, 2001; 286(8): 921 - 929. [Abstract] [Full Text] [PDF]

				C. C. Solorzano, C. H. Baker, R. Tsan, P. Traxler, P. Cohen, E. Buchdunger, J. J. Killion, and I. J. Fidler Optimization for the Blockade of Epidermal Growth Factor Receptor Signaling for Therapy of Human Pancreatic Carcinoma Clin. Cancer Res., August 1, 2001; 7(8): 2563 - 2572. [Abstract] [Full Text] [PDF]

				K. M. Anderson and J. E. Harris Selected Features of Nonendocrine Pancreatic Cancer Experimental Biology and Medicine, June 1, 2001; 226(6): 521 - 537. [Abstract] [Full Text] [PDF]

				S. Tanno, S. Tanno, Y. Mitsuuchi, D. A. Altomare, G.-H. Xiao, and J. R. Testa AKT Activation Up-Regulates Insulin-like Growth Factor I Receptor Expression and Promotes Invasiveness of Human Pancreatic Cancer Cells Cancer Res., January 1, 2001; 61(2): 589 - 593. [Abstract] [Full Text]

				H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text]

				C. J. Bruns, C. C. Solorzano, M. T. Harbison, S. Ozawa, R. Tsan, D. Fan, J. Abbruzzese, P. Traxler, E. Buchdunger, R. Radinsky, et al. Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma Cancer Res., June 1, 2000; 60(11): 2926 - 2935. [Abstract] [Full Text] [PDF]

				S. M. Gapstur, P. H. Gann, W. Lowe, K. Liu, L. Colangelo, and A. Dyer Abnormal Glucose Metabolism and Pancreatic Cancer Mortality JAMA, May 17, 2000; 283(19): 2552 - 2558. [Abstract] [Full Text] [PDF]

				J. Okami, H. Yamamoto, Y. Fujiwara, M. Tsujie, M. Kondo, S. Noura, S. Oshima, H. Nagano, K. Dono, K. Umeshita, et al. Overexpression of Cyclooxygenase-2 in Carcinoma of the Pancreas Clin. Cancer Res., August 1, 1999; 5(8): 2018 - 2024. [Abstract] [Full Text] [PDF]

				S. E. Damon, L. Maddison, J. L. Ware, and S. R. Plymate Overexpression of an Inhibitory Insulin-Like Growth Factor Binding Protein (IGFBP), IGFBP-4, Delays Onset of Prostate Tumor Formation Endocrinology, August 1, 1998; 139(8): 3456 - 3464. [Abstract] [Full Text] [PDF]

				N. Lamharzi, A. V. Schally, M. Koppan, and K. Groot Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors PNAS, July 21, 1998; 95(15): 8864 - 8868. [Abstract] [Full Text] [PDF]

				S. R. Plymate, V. L. Bae, L. Maddison, L. S. Quinn, and J. L. Ware Reexpression of the Type 1 Insulin-Like Growth Factor Receptor Inhibits the Malignant Phenotype of Simian Virus 40 T Antigen Immortalized Human Prostate Epithelial Cells Endocrinology, April 1, 1997; 138(4): 1728 - 1735. [Abstract] [Full Text] [PDF]

				R. S. Warren, H. Yuan, M. R. Matli, N. Ferrara, and D. B. Donner Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1in Colorectal Carcinoma J. Biol. Chem., November 15, 1996; 271(46): 29483 - 29488. [Abstract] [Full Text] [PDF]

				Y. Pommier, G. Kohlhagen, P. Pourquier, J. M. Sayer, H. Kroth, and D. M. Jerina Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages PNAS, February 29, 2000; 97(5): 2040 - 2045. [Abstract] [Full Text] [PDF]